Damora Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Damora Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($3.13M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($3.44M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.53M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($3.88M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($5.34M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.48M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($8.14M) | Nov 1, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($10.74M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.99M) | Apr 29, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($13.73M) | Nov 6, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($16.89M) | Jul 31, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($16.94M) | Apr 28, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($12.70M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($12.30M) | Jul 29, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($13.35M) | Apr 29, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($11.65M) | Nov 4, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($5.94M) | Aug 5, 2021 |
| Q3 | 2020 | Jun 30, 2020 | ($11.61M) | Dec 11, 2020 |
| Q1 | 2021 | Mar 31, 2020 | ($5.67M) | May 4, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($4.11M) | Dec 11, 2020 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($3.16M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($3.42M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.60M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($3.84M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($5.58M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.74M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($8.58M) | Nov 1, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($11.16M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($13.49M) | Apr 29, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($13.62M) | Nov 6, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($17.12M) | Jul 31, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($16.94M) | Apr 28, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($12.94M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($12.27M) | Jul 29, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($13.55M) | Apr 29, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($10.17M) | Nov 4, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($6.34M) | Aug 5, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($5.83M) | May 4, 2021 |
| Q3 | 2020 | Sep 30, 2019 | $4.83M | Dec 11, 2020 |